| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OLIG1 |
| Uniprot No | Q8TAK6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-105aa |
| 氨基酸序列 | MLRPQRPGDLQLGASLYELVGYRQPPSSSSSSTSSTSSTSSSSTTAPLLPKAAREKPEAPAEPPGPGPGSGAHPGGSARPDAKEEQQQQ |
| 预测分子量 | 11.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OLIG1重组蛋白的3篇代表性文献(信息基于公开研究总结，非真实文献)：
---
1. **标题**：*OLIG1重组蛋白促进少突胶质细胞分化的功能研究*
**作者**：Q.R. Lu, D.H. Rowitch
**摘要**：研究通过表达纯化OLIG1重组蛋白，发现其能显著诱导体外培养的神经干细胞向少突胶质细胞分化，并促进髓鞘相关基因表达，提示其在神经修复中的潜在应用。
2. **标题**：*OLIG1的DNA结合结构域重组蛋白的晶体结构解析*
**作者**：T. Yamaguchi, K. Nakayama
**摘要**：报道了OLIG1重组蛋白中DNA结合结构域的晶体结构，揭示其与靶基因启动子结合的关键氨基酸残基，为设计调控少突胶质细胞生成的分子工具提供结构基础。
3. **标题**：*OLIG1重组蛋白在脑损伤模型中的治疗作用评估*
**作者**：L. Chen, M. Goldman
**摘要**：在小鼠脑白质损伤模型中，注射OLIG1重组蛋白可增强内源性髓鞘再生能力，改善运动功能，表明其作为多发性硬化等脱髓鞘疾病的治疗候选分子。
---
**注**：以上文献为示例，实际研究需通过PubMed或学术数据库检索真实发表论文。
OLIG1 (Oligodendrocyte lineage transcription factor 1) is a key regulatory protein involved in the development and differentiation of oligodendrocytes, specialized glial cells responsible for myelination in the central nervous system (CNS). As a member of the basic helix-loop-helix (bHLH) transcription factor family, OLIG1 plays a critical role in specifying oligodendrocyte progenitor cells (OPCs) and promoting their maturation into myelinating oligodendrocytes. It is closely associated with its homolog OLIG2. but exhibits CNS-specific expression patterns, particularly in regions like the brain and spinal cord.
Recombinant OLIG1 protein is engineered through molecular cloning techniques, typically expressed in bacterial (e.g., E. coli) or mammalian cell systems to ensure proper folding and post-translational modifications. The purified protein retains functional domains, including the conserved bHLH region essential for DNA binding and dimerization with other transcription factors. Researchers utilize recombinant OLIG1 to study oligodendrocyte biology, myelination mechanisms, and remyelination processes in neurodegenerative disorders such as multiple sclerosis (MS) and leukodystrophies. Its applications extend to in vitro models for screening potential therapeutics targeting demyelination diseases, as well as in stem cell differentiation protocols to generate oligodendrocyte lineages for regenerative medicine. Validation of recombinant OLIG1 typically includes SDS-PAGE, Western blotting, and functional assays confirming its ability to regulate myelin-related gene expression. Current research also explores its potential in gene therapy approaches for CNS repair.
×
